Patients’ characteristics
| Characteristics | Value |
| Age (years), median (range) | 64 (42–83) |
| Age ≥75 years, n (%) | 16 (21) |
| Male sex, n (%) | 59 (79) |
| Histological type, n (%) | |
| Non-squamous cell carcinoma | 63 (84) |
| Squamous cell carcinoma | 12 (16) |
| Prior surgery, n (%) | 15 (20) |
| Prior thoracic radiotherapy, n (%) | 24 (32) |
| PDL1 expression, n (%) | |
| <50% | 15 (20) |
| ≥50% | 31 (41) |
| Unknown | 29 (39) |
| Brain metastases, n (%) | 25 (33) |
| Treated with radiotherapy | 24 (32) |
| No radiotherapy treatment | 1 (1) |
| Lines of previous systemic therapy, n (%) | |
| 0 | 13 (17) |
| 1 | 48 (64) |
| ≥2 | 14 (19) |
| Immunotherapy, n (%) | |
| Pembrolizumab | 42 (56) |
| Nivolumab | 33 (44) |
PDL1, programmed death receptor ligand 1.